Products / Programs
Complix’s drug development is currently focused on cancer and autoimmune disease, therapeutic areas that offer a significant opportunity for new therapeutic interventions based on addressing currently undruggable targets.
Programs / Oncology
Complix is developing Cell Penetrating Alphabodies (CPABs) as potentially revolutionary therapeutics for the treatment of cancer.
Work to-date has shown that CPABs specific for selected cancer targets are active in a variety of tumor cells, whilst non-toxic to normal human cells.
For one of its initial programs in oncology Complix has selected the intracellular target protein MCL-1. MCL-1 is an important regulator of cellular apoptosis, determining whether a cell survives or dies. In cancer cells, MCL-1 is often overexpressed and prevents these cells from entering the apoptosis phase and dying. Complix has designed and produced CPABs which strongly antagonize MCL-1, and consequently induce apoptosis (cell death) in the cancer cells.
MCL-1 is a validated drug target which is implicated in a number of cancer indications including several types of hematological cancers. Initial in-vivo data generated with Complix´ anti-MCL-1 CPABs suggest they should have a good safety profile.
Products / Autoimmune
Complix’ most advanced program is CMX-02, a potential treatment for severe autoimmune disease. CMX-02 is a bispecific Alphabody-antibody fusion protein that is currently in advanced preclinical development. CMX-02 combines the benefits of two major classes of therapeutic proteins and simultaneously targets two key cytokines in the inflammation cascade that lies at the basis of autoimmunity, namely TNFα and IL-23. Complix believes that CMX-02, with its dual activity, can tackle both the upstream cascade initiation as well as the more downstream acute phase of the disease, and, therefore, has the potential to offer major clinical benefits over existing therapies in the autoimmune disease area.